GILEAD SCIENCES, INC. Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
GILEAD SCIENCES, INC. (GILD) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of -$22.00 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-07.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2025-05-07
- GILEAD SCIENCES, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2025-03-31 was -$22.00M, a 161.11% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2024-12-31 was $66.00M, a 2100.00% increase year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2024-09-30 was -$7.00M, a 120.00% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2024-06-30 was $29.00M, a 25.64% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2024 was $124.00M, a 65.33% increase from fiscal 2023.
- GILEAD SCIENCES, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2023 was $75.00M, a 14.77% decline from fiscal 2022.
- GILEAD SCIENCES, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2022 was $88.00M, a 3.53% increase from fiscal 2021.
- GILEAD SCIENCES, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2021 was $85.00M.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | -$22.00M 10-Q · filed 2025-05-07 | $44.00M derived: sum of 2 quarters · filed 2025-05-07 | $37.00M derived: sum of 3 quarters · filed 2025-05-07 | $66.00M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2024-12-31 | $66.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $59.00M derived: sum of 2 quarters · filed 2025-02-28 | $88.00M derived: sum of 3 quarters · filed 2025-02-28 | $124.00M 10-K · filed 2025-02-28 | |
| 2024-09-30 | -$7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $22.00M derived: sum of 2 quarters · filed 2024-11-12 | $58.00M 10-Q · filed 2024-11-12 | $61.00M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2024-06-30 | $29.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $65.00M 10-Q · filed 2024-08-08 | $68.00M derived: sum of 3 quarters · filed 2025-05-07 | $103.00M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2024-03-31 | $36.00M 10-Q · filed 2025-05-07 | $39.00M derived: sum of 2 quarters · filed 2025-05-07 | $74.00M derived: sum of 3 quarters · filed 2025-05-07 | $113.00M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $38.00M derived: sum of 2 quarters · filed 2025-02-28 | $77.00M derived: sum of 3 quarters · filed 2025-02-28 | $75.00M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $35.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $74.00M derived: sum of 2 quarters · filed 2024-11-12 | $72.00M 10-Q · filed 2024-11-12 | $46.00M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | $39.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $37.00M 10-Q · filed 2024-08-08 | $11.00M derived: sum of 3 quarters · filed 2025-02-28 | $63.00M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | -$2.00M 10-Q · filed 2024-05-08 | -$28.00M derived: sum of 2 quarters · filed 2025-02-28 | $24.00M derived: sum of 3 quarters · filed 2025-02-28 | $76.00M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | -$26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $26.00M derived: sum of 2 quarters · filed 2025-02-28 | $78.00M derived: sum of 3 quarters · filed 2025-02-28 | $88.00M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $52.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $104.00M derived: sum of 2 quarters · filed 2023-11-07 | $114.00M 10-Q · filed 2023-11-07 | $125.00M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $52.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $62.00M 10-Q · filed 2023-08-04 | $73.00M derived: sum of 3 quarters · filed 2023-08-04 | $90.00M derived: sum of 4 quarters · filed 2023-08-04 | |
| 2022-03-31 | $10.00M 10-Q · filed 2023-05-03 | $21.00M derived: sum of 2 quarters · filed 2023-05-03 | $38.00M derived: sum of 3 quarters · filed 2023-05-03 | $19.00M derived: sum of 4 quarters · filed 2023-05-03 | |
| 2021-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $28.00M derived: sum of 2 quarters · filed 2023-02-22 | $9.00M derived: sum of 3 quarters · filed 2023-02-22 | $85.00M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$2.00M derived: sum of 2 quarters · filed 2022-11-02 | $74.00M 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | -$19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $57.00M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $76.00M 10-Q · filed 2022-05-04 | ||||
| 2020-12-31 | -$62.00M 10-K · filed 2023-02-22 | ||||
| 2016-09-30 | -$66.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $43.00M derived: sum of 2 quarters · filed 2016-11-07 | -$129.00M 10-Q · filed 2016-11-07 | -$81.00M derived: sum of 4 quarters · filed 2016-11-07 | |
| 2016-06-30 | $109.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$63.00M 10-Q · filed 2016-08-05 | -$15.00M derived: sum of 3 quarters · filed 2016-08-05 | $37.00M derived: sum of 4 quarters · filed 2016-08-05 | |
| 2016-03-31 | -$172.00M 10-Q · filed 2016-05-06 | -$124.00M derived: sum of 2 quarters · filed 2016-05-06 | -$72.00M derived: sum of 3 quarters · filed 2016-05-06 | -$182.00M derived: sum of 4 quarters · filed 2016-05-06 | |
| 2015-12-31 | $48.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $100.00M derived: sum of 2 quarters · filed 2016-02-24 | -$10.00M derived: sum of 3 quarters · filed 2016-02-24 | $369.00M 10-K · filed 2016-02-24 | |
| 2015-09-30 | $52.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$58.00M derived: sum of 2 quarters · filed 2015-11-04 | $321.00M 10-Q · filed 2015-11-04 | $487.30M derived: sum of 4 quarters · filed 2016-02-24 | |
| 2015-06-30 | -$110.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $269.00M 10-Q · filed 2015-08-05 | $435.30M derived: sum of 3 quarters · filed 2016-02-24 | $648.32M derived: sum of 4 quarters · filed 2016-02-24 | |
| 2015-03-31 | $379.00M 10-Q · filed 2015-05-08 | $545.29M derived: sum of 2 quarters · filed 2016-02-24 | $758.32M derived: sum of 3 quarters · filed 2016-02-24 | $792.80M derived: sum of 4 quarters · filed 2016-02-24 | |
| 2014-12-31 | $166.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $379.32M derived: sum of 2 quarters · filed 2016-02-24 | $413.81M derived: sum of 3 quarters · filed 2016-02-24 | $421.00M 10-K · filed 2016-02-24 | |
| 2014-09-30 | $213.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $247.51M derived: sum of 2 quarters · filed 2014-11-05 | $254.71M 10-Q · filed 2014-11-05 | $149.84M derived: sum of 4 quarters · filed 2015-02-25 | |
| 2014-06-30 | $34.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $41.68M 10-Q · filed 2014-08-04 | -$63.19M derived: sum of 3 quarters · filed 2015-02-25 | -$138.94M derived: sum of 4 quarters · filed 2015-02-25 | |
| 2014-03-31 | $7.20M 10-Q · filed 2014-05-07 | -$97.67M derived: sum of 2 quarters · filed 2015-02-25 | -$173.43M derived: sum of 3 quarters · filed 2015-02-25 | ||
| 2013-12-31 | -$104.87M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | -$180.62M derived: sum of 2 quarters · filed 2015-02-25 | -$99.00M 10-K · filed 2015-02-25 | -$99.23M 10-K · filed 2014-02-25 | |
| 2013-09-30 | -$75.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $5.87M 10-Q · filed 2013-10-31 | |||
| 2013-06-30 | $81.62M 10-Q · filed 2013-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |